

Index

- 1**
17-kDa 9-27/leu13 355
- 2**
2'-5'-oligoadenylate synthetase 210 ff.
– (2'-5'-OAS) 150
– – ribonuclease (RNase) L 231 ff.
2-5A synthetase 356
- 4**
4E-BP1 218
- 9**
96-well microtiter plates 363, 363 ff.
- a**
A46R protein 250
A52R protein 250
A549 cell line 355 f., 359, 377
activating protein 1 (AP-1) 35
AD *see* atopic dermatitis
Adenovirus 248
– E3 protein 248
– E1A protein 248
– VAI RNA 248
African green monkey cell line, Vero 358
AK-1 358
Akt 218
alkaline phosphatase 357
antiapoptotic effect 219 ff.
antibodies to IFN- α 391
antibodies to IFN- β 392
antibodies to self-antigen 376
antiproliferative activity 351, 366
antiproliferative assay 351, 352, 353 ff.,
354
antitumor agent 277
antiviral 227 ff.
– 2'-5'-OAS183
– 2'-5'-OAS/RNase L 186
– ADAR-1 186, 188
– IFITs 188
– IRS-P13K 183
– ISG-20 186, 188
– JAK-STAT 183
– Mx 187
– MxA 183
– p38MAPK 183
– P56 186
– PKR 183, 186
– PLSCR-1 186, 188
– RNase L 183
– TRAIL 186, 188
– Viperin 186
antiviral activity 365
IFN- λ 142
antiviral agent 277
antiviral assay 349 ff., 351 f., 354, 359, 364 ff.,
366, 377
– challenge virus 349
antiviral protection 152
antiviral response 58, 141 ff., 150 f., 153
apoptosis 207 ff., 211 ff.
areas for IFNAR-1 and IFNAR-2 binding
389
arenavirus 242 ff.
ARF 209 ff.
assay 345, 349
assay design and data analysis 363
assays based on intracellular signaling
intermediates 361
ATF 11
ATF4 214
atopic dermatitis (AD), IgE 321
– Th1 response 321
– Th2 response 321
AU-rich element 15
avian Newcastle disease virus 232 ff.

b

B18R protein 249 ff.
 bacille Calmette-Guerin 125
 basal cell carcinoma (BCC) 292
 BFP 127
 BICP0 protein 251
 bioimmunoassays 354 ff., 358
 biological activities, antiproliferative activity
 344 ff.
 – antitumor activity 345
 – antiviral activity 344
 – immunomodulatory activity 345
 BP *see* lipid-binding protein
 Bunyamwera virus 244
 Bunyavirus 242 ff.
 Burkitt's lymphoma-derived B cell line Daudi
 352

c

C protein 232 ff.
 cAMP response element modulation protein
 (CREM) activating transcription factor (ATF)
 39
 cancer 157, 220
 caspase activation and recruitment domains
 (CARD) 59
 cell differentiation 278
 cell proliferation 278
 cell viabilities 208
 CHB *see* chronic hepatitis B
 CHC 288
 CHD 290
 chimeric receptor 122 ff.
 chromosome *see* YAC
 chronic granulomatous disease (CGD) 311
 chronic hepatitis (CHB) 286
 – Hepatitis B virus (HBV) 327
 – Hepatitis C virus (HCV) 327
 chronic myeloid leukemia (CML) 294
cis-trans peptidyl-prolyl isomerase (PPIase)
 activity 46
 class I MHC (HLA) molecules 153
 class II 113 ff.
 class II cytokine receptor family (CRF2), CRF2
 cytokines 142 ff.
 – ligands 142
 clinical grade, IFN products 348 ff.
 clinical samples, bronchial lavage fluids 348
 clinical trials, IFN- γ 309 ff.
 clinical trials of IFN- γ 309
 clotting factor VIII 376
 CML 294
 coded duplicates 363
 condyloma acuminata 296

constant antibody method 380
 constant IFN method 379
 coronavirus 246
 CPE 351, 352
 CPE reduction (CPEr) assay 351 f., 365
 CpG oligodeoxynucleotides (ODNs) 57 f.
 CREB-binding protein (CBP/po300) 40 f.
 CRF2 *see* class II cytokine receptor family
 CRID (coding region instability determinant)
 elements 15
 CrkL pathway, C3G-Rap1 179
 – STAT-5 179
 cyclophilin B (CypB) 46
 cytokines 113
 Cytomegalovirus, gB protein 251
 – IE86 protein 251
 – pp65 protein 251
 cytotoxic cell activity 278

d

Dami 353
 Daudi cell line 353
 DCs 152
 Dengue virus 153, 244
 development of antibodies during IFN therapy
 390
 dose-response curve 363 ff.
 double-stranded (ds) RNA 210, 212
 double-stranded (ds) RNA-activated protein
 kinase (PKR) 150

e

E1A protein 248
 E2 glycoprotein 246
 E3 protein 248
 E6 protein 252
 E7 protein 252
 EAHy296 355
 EBER-1 RNA 252
 EBNA-2 protein 252
 Ebola virus 232 ff.
 – VP35 protein 242
 EBV *see* Epstein-Barr virus (EBV)
 eIF-2 α 212 ff., 214
 eIF-4E 218
 ELISA 356, 359, 361
 – luciferase 357
 – PACE 361
 EMCV *see* encephalomyocarditis virus
 (EMCV)
 encephalomyelitis disseminata 297
 encephalomyocarditis virus (EMCV) 123, 153,
 377
 endpoint analysis 365

- enhanceosome 40
 enzyme expression and reporter gene assay 356
 epigenetic regulation, chromatin 88, 89
 – DNA methylation 88, 89
 – DNase I hypersensitivity 89
 – γ promoter 89
 – histone acetylation 88, 89
 epitope 375
 epitope analysis 388
 Epstein-Barr virus (EBV) 47, 251 ff., 295, 297
 – EBER-1RNA 252
 – EBNA-2 protein 252
 – LMP-1 protein 252
Escherichia coli β -galactosidase 359
 experimental analyses of neutralization 383
- f**
- FDA-approved indications for IFNs 310 ff.
 fibroblast IFN 3 f.
 filovirus 232 ff.
 flavivirus 244
 FLICE-inhibitory protein (vFLIP) 252
 fluorescence emission spectra 125 ff.
 fluorescence resonance energy transfer (FRET) 126
 foot and mouth disease virus 244
- g**
- β -galactosidase 359
 GAS116 ff., 209
 – γ -activated sequence 150
 GATA-3 39
 GFP 127
 glial fibrillary protein (GFAP) 359
 glioblastoma cell line 354, 356, 357
 glycoprotein gB 251
 glycosylation, post-translational modifications
 IFNs 23
 granulocyte macrophage colony-stimulating factor (GM-CSF) 376
 growth-inhibitory 188
 – AIM-2 190
 – Bak 190
 – Bax 190
 – Bcl-1 190
 – C3G-Rap1 189
 – caspases 190
 – CDK 2 189
 – CML 189
 – Crk 189
 – E2F 189
 – FADD 190
 – Fas 190
 – HIN-200 190
 – IFI-16 190
 – IFIX- α 1 190
 – IP6K2 190
 – IRF-1 190
 – IRF-5 190
 – MND A 190
 – *c-myc* 189
 – p15 189
 – P202-E2F 190
 – p21 189
 – p27 189
 – p38MAPK 189
 – PML 189
 – Rap1 189
 – STAT-5 189
 – TRAIL 189
 – Vav 189
 – XAF-1 190
- h**
- hairy cell leukemia (HCL) 290
 HBV *see* Hepatitis B virus
 HCL *see* hairy cell leukemia
 HCV *see* Hepatitis C virus
 HDV *see* Hepatitis δ virus
 HeLa cells 216
 Hendra virus 232 ff.
 – V protein 241
 Hepadnavirus 248
 Hepatitis B virus (HBV) 248, 286 f.
 – chronic (CHB) 286
 Hepatitis C virus (HCV) 59, 244 ff.
 – chronic (CHC) 157, 288
 – Core protein 245
 – NS3/4A protein 245
 – NS3A protein 245
 – NS5A protein 245
 Hepatitis δ virus (HDV) 290
 Herpes simplex virus 250 ff.
 – B-ICP0 protein 251
 – ICP0 protein 251
 – ICP34.5 protein 251
 – US11 protein 251
 high-mobility-group protein [HMGI(Y)] 4, 40
 HIV *see* human immunodeficiency virus
 HIV-1 247
 horseradish peroxidase 357
 HPIV-2, V protein 236 ff., 237
 HPIV-3, C protein 236 ff., 237
 HPV *see* human papillomavirus
 human colon adenocarcinoma cell line, COLO 205 354
 human cytomegalovirus 250 ff.

- human erythroleukemic TF-1 cell line 353
 - human erythropoietin 376
 - human glioblastoma cell line 357, 359
 - human herpesvirus 8 251 ff.
 - Kaposi's Sarcoma-associated herpesvirus (KSHV) 251 ff.
 - human immunodeficiency virus (HIV) 247, 295
 - TAR RNA 248
 - TAT protein 247
 - human insulin 376
 - human lung carcinoma cell line, A549 354
 - human megakaryoblastic UT-7/EPO cell line 353, 354
 - human megakaryocytic cell lines, Dami 353
 - MEG01 353
 - human papillomavirus (HPV) 295 f.
 - human parainfluenza virus type 2 232 ff.
 - human parainfluenza virus type 3 232 ff.
 - human promyelocytic leukemia HL60 353
 - human simplex virus (HSV) type I 47
 - human T cell leukemia virus 295
 - human tumor-derived cell line 356
 - promoter 20
 - protein 73 ff.
 - purification 75 ff.
 - resistance to pathogens 35
 - STAT signaling 26
 - structure 73 f.
 - toxicity 298
 - virus-mediated activation 41
- IFN production, NIPC 167
- pDCs 167
 - IFN products, clinical-grade 348
 - excipient protein 348
 - IFN receptor 39
 - IFN receptor recognition peptide 168
 - IFN regulatory factor *see* IRF
 - IFN signal transduction pathway 50, 358
 - JAK-1 and -2, and TYK-2 tyrosine kinases 341 ff.
 - IFN therapy 220
 - IFN- α 16, 21 ff., 24, 35, 46 f., 57, 73, 75, 146, 153, 154, 157, 289, 290
 - induction 55
 - leucocyte IFN 7 ff.
 - pharmacokinetics 284
 - promoter 11 ff.
 - therapy 288 ff.
 - viral infection 40, 144
 - virus-mediated induction 15
 - IFN- α/β 39
 - IFN- β 7, 16, 21 f., 24, 35, 46 f., 51, 53, 58 f., 73, 146, 151, 153, 154
 - immunoregulation 21
 - induction 55, 57
 - pharmacokinetics 285
 - production 21
 - promoter 11 ff., 40, 59
 - response 21
 - viral infection 144
 - virus-inducible 39
 - IFN- β 1, therapy 297
 - IFN- δ 10, 16, 24
 - IFN- e 9, 16, 24
 - IFN- γ 217
 - adverse reactions 311
 - aerosolized 311
 - antitumor defenses 144
 - Cell-DC crosstalk 97
 - DC presentation 97 ff.
 - gene structure and regulation 86, 88
 - IFN- γ/β 311
 - immunity 144
 - in T_h cell development 95 f.
 - mRNA 85
 - PBL- γ 311
- i*
- ICAM-1 vascular cell adhesion molecule (VCAM)-1 355
 - ICP0 protein 251
 - ICP34.5 protein 251
 - ideopathic pulmonary Fibrosis (IPF) 322
 - IE86 protein 251
 - IFN activation pathway 46
 - IFN bioassays, antiviral assay 377
 - MxA 377
 - IFN (Interferon) 51, 73 ff.
 - activation 35
 - amplification loop 59
 - autocrine and paracrine manner 152
 - divergence 20
 - evolution of family 156
 - expansion 20
 - expression 20
 - fibroblast IFN 3 f.
 - gene subfamily 16
 - genes 85
 - IFN- α 3 ff.
 - immune response 35
 - induced mutation 21
 - leukocyte IFN 3
 - leukocyte-derived 75
 - long-acting 78
 - lymphoblastoid 76
 - natural mutation 21
 - production 75 ff.

- role on tumor development and growth, angiogenesis 100 ff.
- signal transduction 90 ff.
- IFN- γ -activated factor (GAF) 39
- IFN-induced signaling pathways 342
- IFN-inducible proteins 341, 342 ff., 354 ff.
 - 2'-5'-OAS343
 - 2'-5'-oligoadenylate synthetase (2'-5'-OAS) 344
- antigens 354
- antiproliferative activity 345
- assays 354
- Cyclin-dependent kinase (CDK)-2 345
- encephalomyocarditis virus (EMCV) 344
- ICAM-1 343, 354
- intercellular adhesion molecule (ICAM)-1 345
- IRF-1 345
- MHC class I (HLA-A, -B, -C) 343
- MHC class II (HLA-DR) 343
- β_2 -microglobulin 343, 354
- β_2 -microglobulin, class I and II MHC antigens 345
- Mx 343 f.
- MxA 344
- peptide initiation factor, eIF-2 344
- PKR 343 f.
- RNase L 344
- vesicular stomatitis virus (VSV) 344
- IFN- κ 16
 - intron 8
 - transcriptional regulation 8
- IFN- λ 141, 151, 154
 - antiviral activity 142, 153
 - genomic structure 145
 - viral infection 144
- IFN- λ antiviral system 156
 - murine 154
- IFN- λ receptor, IL-28R 146 ff.
- IFN- λ receptor complex, signaling 148
- IFN- λ 1 142 f.
- IFN- λ 2 142 f.
- IFN- ν 10, 16
- IFN- ω 8, 16, 22
- IFN-producing cells (IPC) 4
- IFN- θ 9, 16, 24
- IFN-regulatory factor *see* IRF
- IFN-regulatory factor (IRF) binding sites 11
- IFN-responsive gene 150
- IFN-specific cell surface receptors, type II cytokine receptor family (CRF2) 340
- IFN-stimulated gene factor 3 (ISGF-3) 39, 142, 150
- IFN-stimulated genes (ISGs) 19, 39, 59
- IFN-stimulated responsive element (ISRE) 39, 116 ff., 209, 358
- IFN- τ 9, 22
 - pregnancy 16
 - trophoblast IFN 20
- IFNAR receptor 4, 20
- IFNAR-1 74
 - Gb₂ 174
 - Gb₃ 174
- IFNAR-2, IFN- α 172
 - IFN- α 2 170
 - IFN- β 173
- IRRP-1 168
- IRRP-3 168
- I κ b α kinase complex (KK) 55
- IKK ϵ 41 ff., 58, 59
- immune response 35, 50
- immune stimuli 144
- immunity 144
- immunoassays for non-NAbs 387
- immunomodulation
 - B cell 191
 - B lymphocyte 192
 - DCs 192
 - granulocytes 191
 - IFN- β knockout 190
 - IFNAR-1-deficient 190
 - macrophages 191
 - MHC class I 192
 - myeloid 190
 - NK cells 192
 - plenic architecture 191
 - T lymphocyte 192
 - TNF- α 190
- index of neutralization 379
- indoleamine 2,3-dioxygenase (IDO) 356
- inducible protein expression 366
- infection following serious trauma 318
 - *Bacteroides fragilis* 319
 - *Escherichia coli* 319
 - *Klebsiella pneumoniae* 319
 - *Pseudomonas aeruginosa* 319
- influenza virus 57, 153, 242 ff.
 - NS1 protein 243
- innate immunity 227
- interferon *see* IFN
 - interferon regulatory factor *see* IRF
 - interleukin 142, 228 ff.
 - IL-1 receptor family 50
 - IL-15 39
 - IL-28A 113 ff., 127
 - IL-29 113 ff.
 - IL-1 β 228 ff.

interleukin-1 β (IL-1 β) 228 ff.
 International Units (IU) 364, 378
 intron 6
 IPC *see* IFN producing cell
 IPF *see* idiopathic pulmonary fibrosis
 IRAK1 53, 57
 IRAK4 57
 IRF (IFN regulatory factor) 35, 41, 51, 150, 342
 – apoptosis 41
 – cell cycle 41
 – tumor suppression 41
 IRF-1 217
 IRF-3 15, 40 ff., 51, 57, 59, 228 ff., 230 ff.
 – autoinhibitory interaction 41
 – autoinhibitory structure 46
 IRF-5 46 f., 57
 IRF-7 47 ff., 57, 58
 – transactivation activity 49
 IRF-9 350, 358
 IRF-association domain (IAD) 41
 IRF family 40, 48
 IRSp pathway, 4E-BP1 181
 – eIF-4E 181
 – Grb-2 181
 – IRS-1 179
 – IRS-2 179
 – mTOR 181
 – p70S6 181
 – PI3K 179
 ISGF-3 *see* IFN-stimulated gene factor 3
 ISGs *see* IFN-stimulated genes
 ISRE *see* IFN-stimulated responsive element
 IU 365

j

JAK *see* Janus kinase
 JAK-1 361
 JAK-1 tyrosine kinase 148 ff.
 JAK-STAT signal transduction 142 ff., 175, 177 f., 350
 Janus Kinase (JAK) 114
 – JAK-1 114 ff.
 – JAK-2 114 ff.
 – signal transducers and activators of transcription (STAT) 230 ff.
 – STAT signaling 39
 – TYK-2 114 ff., 116
 Jun 11
 c-Jun N-terminal kinase (JNK) 55

k

K1L protein 249 ff.
 Kaposi sarcoma (KS) 292

Kaposi's Sarcoma-associated herpesvirus (KSHV) 251 ff.
 Kawade 382
 kinase receptor activation (KIRA) assay 361
 KIRA assay 361, 361 ff., 362
 KS-associated herpesvirus (KSHV) 293
 KSHV, vFLIP 252
 – vIRFs 252

l

Laboratory Unit (LU) 365, 377
 laryngeal papillomatosis 295
 latent membrane protein 252
 LBP *see* lipid-binding protein
 leishmaniasis 317
 leprosy 314
 leukemic reticuloendotheliosis 290
 leukocyte IFN 3 f.
 limitin *see* IFN- θ
 lipid-binding protein (LBP) 53
 lipopolysaccharide (LPS) 53, 144
 LPS *see* lipopolysaccharide
 luciferase 358, 359, 360
 luciferin 359, 360

m

M1 myeloid cell line 353
 MAbs 377
 malignant melanoma 292
 MAPK 219
 MAPK kinase 55
 MAPK pathway 181
 MCF-7 208
 Measles virus 232 ff.
 – V protein 239
 measurement of antibodies to interferon 375
 measurement of biological activities
 – antiproliferative activity 351
 – antiproliferative assays 351
 – antiviral assay 351
 – antiviral assay cell/virus combinations 350
 – CPE 351
 – CPE reduction (CPER) assay 351
 – EMCV 350, 351
 – JAK-STAT signaling pathway 350
 – MTS(3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulphophenyl]-2H-tetrazolium inner salt 351
 – MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) 351
 – SFV 350
 – SINV 350
 – viral cytopathic effect (CPE) 351
 – virus yield reduction assay 351

- VSV 350
 - measurement of interferon activities
 - antiviral assay 349
 - biological standards for IFNs 345
 - general considerations 345
 - introduction 339
 - practical considerations for IFN preparations 348
 - MEG01 353
 - melanoma differentiation-associated Gene-5 (mda-5) 59
 - MHC class I 116 ff.
 - β_2 -microglobulin 355
 - mitogen-activated protein kinase (MAPK) 53
 - monoclonal Abs (MAbs) 375
 - MS 297
 - secondary-progressive MS (SPMS) 298
 - mTOR 218 ff.
 - MTS(3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulphophenyl]-2H-tetrazolium inner salt) 351
 - MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) 351
 - multiple myeloma (plasma cell myeloma) 293
 - multiple sclerosis (MS), relapsing-remitting MS(RRMS) 297
 - Mumps virus 232 ff.
 - V protein 238
 - mutated residues reducing mAb binding 389
 - MV virus, V protein 239
 - Mx protein 150 f., 231 ff.
 - MxA 355, 356, 357, 359, 377
 - MxA assay 356
 - MxA-luciferase 360
 - Mxo 355, 358
 - Mycobacterium avium* infection 315
 - Mycobacterium* infections 314
 - mycosis fungoides (MF) 296
 - MyD88 adaptor-like protein (MAL) 53
 - MyD88 induction 57
- n**
- N1L protein 250
 - NAbs *see* neutralizing antibodies
 - natural IFN-producing cells (NIPC) 144, 152
 - natural killer (NK) cells 278
 - NDV *see* Newcastle disease virus
 - negative regulatory domains (NRD1), promoter 40
 - neutralization 377
 - neutralization bioassay design 378
 - neutralization by Ab 377
 - neutralizing antibodies (NAbs) 285, 375
 - neutralizing antibody titration 378
 - Newcastle disease virus (NDV) 47 ff., 75, 238
 - NF- κ B 11, 15, 35, 40, 53, 213, 218, 227 ff.
 - NF- κ B signaling pathway 51 ff.
 - NF- κ B-regulating factor (NRF) 40
 - NHL 295
 - Nipah virus, P protein 241
 - V protein 241
 - Wprotein 241
 - NIPCs *see* natural IFN-producing cells
 - p-nitrophenylphosphate (NPP) 359
 - non-Hodgkin's lymphoma (NHL) 295
 - nonsegmented negative-strand RNA viruses 232
 - nonstructural protein 240
 - NS1 protein 232 ff., 240
 - NS2 protein 232 ff., 240
 - NS3/4A protein 245
 - NS3A protein 245
 - NS5A 245 f.
 - NSs, NS α protein 242 ff.
 - nuclear factor (NF)- κ B *see* NF- κ B
 - nuclear factor of activated T cells (NF-AT) 35
- o**
- oncology indications 329
 - oncolytic virus 214
 - opportunistic infections in HIV disease 317
 - orthomyxovirus 242 ff.
 - Osteopetrosis 313
- p**
- P protein 232 ff.
 - p53 209 ff., 211
 - PAbs *see* polyclonal antibodies
 - PACE 361
 - PACT/RAX 212
 - papillomavirus, E6 protein 252
 - E7 protein 252
 - parallelism 365
 - paramyxovirus 232 ff.
 - PARP 208
 - pathogen-associated molecular patterns (PAMPs) 50
 - pharmacokinetics 284 f.
 - phosphatidylinositol-3-kinase 218, 240
 - phosphatidylinositol-3-kinase pathway (PI3K) 51
 - phosphospecific antibody cell-based 361
 - picornaviruses 244
 - PKC, PKC- δ 182
 - PKR 212 ff., 228 ff., 356
 - plasma cell myeloma *see* multiple myeloma
 - plasmacytoid DCs (pDCs) 144
 - plate effect 363

- poliovirus 244
 polyclonal antibodies (PAbs) 375, 377
 positive regulatory domains (PRDs) 11, 40
 post-transcriptional regulation 90
 potency 346, 348 f., 363 ff.
 potency determination 361
 poxvirus 248
 pp65 251
 PRD *see* positive regulatory domains
 PRDI-like elements 15
 pro-inflammatory cytokines 57 f.
 pro-inflammatory genes 51 ff.
 proliferation 208
 prostate cancer 211
 protein induction 342
 protein kinase B 218
 protein kinase C 240
 protein synthesis 216
 pseudogenes 3 ff.
 psoralen and UV A (PUVA) therapy 296
- r**
- Rabies virus 232 ff.
 – P protein 242
 radiation-induced fibrosis 326 f.
 RANTES39, 51
 rapamycin 218 ff.
 receptor complex 114 ff.
 receptor-interacting protein (RIP-1) 51
 receptors, “non-receptor” tyrosine kinases of
 the Janus, JAK 341
 – TYK 341
 recommended NAb procedure 386
 reference preparation 346
 regulatory landscape 365
 renal cell carcinoma (RCC) 291
 reovirus 247
 reporter gene assay 358, 359, 360, 366
 reporting of neutralization results 383
 respiratory syncytial virus 232 ff.
 retinoic-inducible gene (rig)-I, signaling 58
 retrovirus 247
 rhabdovirus 232 ff.
 ribonuclease (RNase) 210 ff.
 rift valley fever virus, NS α protein 242 ff.
 RNA helicase activity, DExD/H box 59
 RNase 356
 RSV, nonstructural protein 240
- s**
- SARS (severe acute respiratory syndrome) 18
 – coronavirus (SARS-CoV) 246 ff.
 scaffold/matrix associated regions (S/MARs)
 21
 secreted alkaline phosphatase (SEAP) 358 f.
 segmented negative-strand RNA viruses 242
 self-antigen 376
 Sendai Virus 41 ff., 75, 153, 232 ff.
 – C protein 233 f.
 – V protein 233 f.
 severe acute respiratory syndrome *see* SARS
 SFV 350
 signal transducer and activator of transcription
see STAT
 signal transduction 218 ff.
 simian virus 5 232 ff.
 simplest model 382
 simultaneous IFN titration 378
 Sindbis virus (SINV) 153, 350, 377
 Sjögren’s syndrome 299
 solution to the problem of NAb unitage 385
 standard 363, 364
 standardization of neutralization results 383
 STAT knockout mice 178
 STAT (signal transducer and activator of
 transcription) 26, 39, 114, 148 ff., 342, 349,
 361
 – cytoplasmic-nuclear translocation 362
 – STAT translocation 362
 STAT-1 349, 358, 361
 STAT-2 349, 358, 361
 SV5, V protein 234 ff., 236
 systemic sclerosis (SSc) 326
- t**
- T-bet 39
 TAK1 (transforming growth factor- β activated
 kinase) 55
 TAK1-binding protein (TAB2) 55
 TAR RNA 248
 TAT protein 247
 TBK1 41, 58, 59
 Tenfold reduction Units (TRU) 380
 theoretical analyses of neutralization 382
 thermal stability 349
 TIRAP 53
 TLR family 50
 TLR-3, signaling 51
 TLR-4, signaling 53
 TLR-7, signaling 57, 58
 TLR-dependent pathway 35 ff., 58
 TLR-independent pathway 35 ff.
 TLRs (Toll-like receptors) 192, 228 ff.
 TNF *see* tumor necrosis factor
 Toll receptor 50
 Toll-interacting region (TIR) domain 50
 Toll-like receptors *see* TLRs
 TRAF6 51 ff., 57

- TRAIL 116 ff., 207 ff., 215 ff., 220
transformed/tumor-derived cell line 352
– African green monkey cell line, Vero 358
– glioblastoma-derived cell lines 354
– human colon adenocarcinoma cell line COLO 205 354
– human lung carcinoma cell line, A549 354
– mouse L-M cell line 359
transforming growth factor 15
transforming growth factor- β activated kinase
see TAK1
translation-initiation factor eIF-2 α 151
TRIF-related adaptor molecule (TRAM) 55
TRIF/-TICAM-1 51
TRL-9, signaling 58
Tuberculosis (TB) 315
tumor necrosis factor (TNF)- α 53, 207 ff.,
228 ff., 355, 363
TYK-2 117, 358, 361
type I IFN 4 ff., 20, 22 f., 46, 57 f., 142, 277 ff.,
342, 350 ff., 354 ff., 359 ff.
– biological effects 277
– clinical applications 277 ff., 285
– cloned 76
– conserved amino acid residues 22
– constitutive expression 11
– disulfide bond formation 24
– evolution 15
– gene-regulatory regions 11
– genetics 3 ff.
– IFN- α 340
– IFN- β 340
– IFN- δ 4 ff.
– IFN- ϵ 4 ff., 340
– IFN- κ 4 ff., 6, 340
– IFN- ν 4 ff.
– IFN- ω 4 ff., 340
– IFN- θ 4 ff.
– IFN- τ 4 ff.
– inducible expression 11
– inflammation 144
– intron 6
– murine type I Ifn genes 6
– mutation 21
– promoter 11 ff.
– secondary structure 22
– secretion 58
– stimulation 41
– structure 3 ff., 24, 73
– therapeutic potential 157
– type I IFN production 4 ff.
– vertebrate 15
– viral 35
type II IFN 142, 342, 352 f., 359
– IFN- γ 4, 340
– stimulation 41
type III IFN 142, 350 f., 353, 355, 359
– biological activities 152
– IFN- λ 4 ff., 141, 340
- U**
ubiquitin conjugating enzyme complex 55
upstream stimulatory activity (USA) 40
US11 protein 251
- V**
V protein 232 ff.
Vaccinia virus 248 ff.
VAI RNA 248
variable response 363
Vav
– DNA-PK 182
– Ku80 182
– p38MAPK 182
– PKC- δ 182
– Rac1 182
– STAT-1 182
– TYK-2 182
Vero cells 359
vesicular stomatitis virus (VSV) 47 ff., 153,
350, 377
viral cytopathic effect (CPE) 351
viral defense 227
viral infection 11, 40, 51, 58, 141, 144, 286,
295
viral replication 152, 278
vIRFs 252
virus infection 41 f., 154
virus response element (VRE) 11
virus yield reduction assay 351
VP35 protein 232 ff.
VSV *see* vesicular stomatitis virus
- W**
W protein 232 ff.
West Nile virus 244 ff.
– nonstructural protein 246
WHO, biological standards 346
– chick IFN 347
– human IFN 347
– International Standard (IS) 346
– murine (mouse) IFN 347
– rabbit IFN 347
– WHO international collaborative studies
346
– WHO ISs for IFNs 347, 365
WHO ISs 347 ff., 353
– International Units (IU) 347

410 | *Index*

- IS working standard 348
- leukocyte IFN 348
- working standards 347 f.
- WISH or amnion-derived FL cells 377

Y

- YAC, yeast artificial 118
- yeast artificial chromosome 118 ff.
- yin-yang-1 39